ArticleEmerging infectious diseases2023
Molecular Evolution and Increasing Macrolide Resistance of Bordetella pertussis, Shanghai, China, 2016-2022.
Article in Emerging infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antimicrobial resistance inEpidemiology and infection · 2026Pooled it
- IS481-based pertussis positivity transition from preschool to school-aged children and theEmerging microbes & infections · 2026Article
- Pathogenicity and vaccine protection of circulating pertactin- and filamentous hemagglutinin-deficientEmerging microbes & infections · 2026Article
- Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.The Journal of infectious diseases · 2026Article
- Infection prevention and control strategies for multidrug-resistant Gram-negative bacteria in healthcare: a narrative review.JAC-antimicrobial resistance · 2026Review
- Released palmitic acid-mediated TLR4/NF-κB activation enhances the virulence of Bordetella pertussis MT28 lineage.Nature communications · 2026Article
- Severe Pertussis During Early Infancy from a High-Altitude Region: Two Clinical Cases and Literature Review.Journal of clinical medicine · 2026Article
- Epidemiological and clinical characteristics of macrolide-resistant Bordetella pertussis in southern China: an 8-year retrospective study.BMC infectious diseases · 2026Article
- Parent-driven transmission, off-label SMZ-TMP, and severe pertussis prediction in infants under 2 months: a real-world observational cohort of 527 cases.Frontiers in pediatrics · 2026Article
- The 2024-2025 Pertussis outbreak in children in Chengdu: A large-scale retrospective cross-sectional study.PloS one · 2026Article
- Clinical characteristics and macrolide resistance analysis of pertussis in children: a retrospective study.Frontiers in public health · 2026Article
- Comprehensive and innovative post-market surveillance system for atypical respiratory pathogens detecting qPCR panel.PloS one · 2026Article
- Revisiting Whooping Cough: Global Drivers and Implications of Pertussis Resurgence in the Acellular Vaccine Era.Vaccines · 2025Review
- Genomic surveillance reveals global spread of macrolide-resistantJournal of clinical microbiology · 2025Article
- Genomic epidemiology and evolution ofEmerging microbes & infections · 2025Article
- Innovations in pediatric lung health amid global health shifts.World journal of pediatrics : WJP · 2025Article
- Analysis of pertussis surveillance data (2022-2023) in a district of Beijing.BMC infectious diseases · 2025Article
- Genomic insights into Bordetella pertussis evolution and macrolide resistance in Yiwu, China.BMC genomics · 2025Article
- Pertussis-A Re-Emerging Threat Despite Immunization: An Analysis of Vaccine Effectiveness and Antibiotic Resistance.International journal of molecular sciences · 2025Review
- Molecular epidemiology and genomic features of Bordetella pertussis in Tianjin, China, 2023.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resurgence and spread of macrolide-resistant Bordetella pertussis (MRBP) threaten global public health. We collected 283 B. pertussis isolates during 2016-2022 in Shanghai, China, and conducted 23S rRNA gene A2047G mutation detection, multilocus variable-number tandem-repeat analysis, and virulence genotyping analysis. We performed whole-genome sequencing on representative strains. We detected pertussis primarily in infants (0-1 years of age) before 2020 and older children (>5-10 years of age) after 2020. The major genotypes were ptxP1/prn1/fhaB3/ptxA1/ptxC1/fim2-1/fim3-1 (48.7%) and ptxP3/prn2/fhaB1/ptxA1/ptxC2/fim2-1/fim3-1 (47.7%). MRBP increased remarkably from 2016 (36.4%) to 2022 (97.2%). All MRBPs before 2020 harbored ptxP1, and 51.4% belonged to multilocus variable-number tandem-repeat analysis type (MT) 195, whereas ptxP3-MRBP increased from 0% before 2020 to 66.7% after 2020, and all belonged to MT28. MT28 ptxP3-MRBP emerged only after 2020 and replaced the resident MT195 ptxP1-MRBP, revealing that 2020 was a watershed in the transformation of MRBP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.